PF-Atlas › Clinical Trials › NCT03492762
PET Imaging CCR2 in Lung Inflammation
Cu-DOTA-ECL1i · Early Phase 1
Registry ID
NCT03492762
Phase
Early Phase 1
Status
Recruiting
Drug / intervention
Cu-DOTA-ECL1i
Sponsor
Washington University School of Medicine
Start
2018-02-27
Enrollment
110
Locations
1
About this trial
The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03492762 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.